The RB Gene Family in Cancer Initiation
The RB Gene Family in Cancer Initiation
批准号:
7841853
负责人:
JULIEN SAGE
金额:
$27.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-01 至 2012-05-31
关键词:
Abnormal CellAcuteAdenovirusesAdultCandidate Disease GeneCell CycleCell Cycle ArrestCell Cycle ProgressionCell Cycle ProteinsCell Cycle RegulationCell Cycle StageCell physiologyCellsDefectDetectionDiagnostic Neoplasm StagingEarly treatmentEmbryonic DevelopmentEquilibriumFamilyFamily memberFibroblastsFoundationsG1 PhaseGene FamilyGenesGeneticGoalsGrowthHepatocyteHumanLinkLiverMaintenanceMalignant NeoplasmsMediatingMediator of activation proteinMitoticMolecularMusMutant Strains MiceMutateMutationNervous system structureNeuroepithelial, Perineurial, and Schwann Cell NeoplasmNeurogliaNeuronsNormal CellPathway interactionsPatientsPhenotypePlayPopulationProcessProtein FamilyProteinsRBL2 geneRNA InterferenceRetinalRetinoblastomaRetinoblastoma GenesRetinoblastoma ProteinRoleSignal TransductionStagingSystemTestingTranscription CoactivatorTranscription Repressor/CorepressorTransgenic MiceTumor SuppressionTumor Suppressor ProteinsViral Vectorbasecancer initiationcdc Genescell typefetalin vivoinsightknock-downloss of functionmouse modelmutantnerve stem cellnovelp107 proteinpreventprogramsrecombinaseresearch studyresponsesenescencetherapeutic targettumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The retinoblastoma (RB) gene is a potent suppressor of human cancers. While RB is thought to have multiple functions during the cell cycle, the specific functions of RB that are critical for its tumor suppression activity are still unclear. We propose to test the idea that RB and its two related family members p107 and p130 play a pivotal role in preventing cancer initiation in vivo by controlling the transition between the GO and G1 phase of the cell cycle. Specifically, we hypothesize that the acute somatic loss of RB family function leads to defects in both cell cycle exit (G1->GO) and cell cycle re-entry (GO->G1) in critical cell populations, and that these defects may result in the initiation of tumorigenesis. We will test our hypothesis using mouse models with combinations of germline and conditional mutations of RB family genes. This mouse genetic approach will enable us to determine the role of RB family genes in spatially and temporally-defined cell populations. These mouse models will also allow us to recapitulate in vivo the early stages of cancer in humans. Studies in the first Specific Aim will characterize the function of RB family genes in cell cycle exit during embryonic development. RB patients develop retinoblastomas, which are retinal neural tumors, as early as the fetal stage. We will focus our studies on neural progenitors to explore the consequences of loss of RB family function on cell cycle exit and differentiation defects leading to cancer initiation. Studies in the second Specific Aim will determine if the RB family proteins are required for maintenance of differentiation in vivo. Specifically, we will investigate the consequences of acute loss of function of RB family genes on cell cycle re-entry of differentiated hepatocytes in vivo. These studies will be important to determine if some terminally differentiated cells may be at the origin of cancer. Studies in the third Specific Aim will combine molecular approaches and RNA interference in vivo to understand the molecular mechanisms underlying cell cycle re-entry upon loss of RB family function in vivo. We will focus our studies on candidate mediators of cell cycle re-entry in RB family mutant hepatocytes, including the E2F transcriptional activator and the Id2 transcriptional repressor. Understanding the molecular bases and the cellular consequences of the loss of RB family tumor suppressors in vivo will give important and novel insights into the mechanisms of cancer initiation. These studies will further provide the foundation for the detection and treatment of early stages of human cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 2: To determine the consequences of activating Rb function in cancer cells
-
批准号:10597166
-
项目类别:
-
资助金额:$23.44万
-
财政年份:2022
-
负责人:JULIEN SAGE
-
依托单位:
Project 2: To determine the consequences of activating Rb function in cancer cells
-
批准号:10332381
-
项目类别:
-
资助金额:$27.65万
-
财政年份:2022
-
负责人:JULIEN SAGE
-
依托单位:
Core A: Determining and targeting mechanisms controlling cancer cell division
-
批准号:10597192
-
项目类别:
-
资助金额:$23.44万
-
财政年份:2022
-
负责人:JULIEN SAGE
-
依托单位:
Core A: Determining and targeting mechanisms controlling cancer cell division
-
批准号:10332383
-
项目类别:
-
资助金额:$27.65万
-
财政年份:2022
-
负责人:JULIEN SAGE
-
依托单位:
Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies
-
批准号:10696254
-
项目类别:
-
资助金额:$94.33万
-
财政年份:2019
-
负责人:JULIEN SAGE
-
依托单位:
Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies
-
批准号:10463652
-
项目类别:
-
资助金额:$94.61万
-
财政年份:2019
-
负责人:JULIEN SAGE
-
依托单位:
Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies
-
批准号:10013140
-
项目类别:
-
资助金额:$96.39万
-
财政年份:2019
-
负责人:JULIEN SAGE
-
依托单位:
Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies
-
批准号:9814560
-
项目类别:
-
资助金额:$49.02万
-
财政年份:2019
-
负责人:JULIEN SAGE
-
依托单位:
Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies
-
批准号:10238088
-
项目类别:
-
资助金额:$96.46万
-
财政年份:2019
-
负责人:JULIEN SAGE
-
依托单位:
Notch signaling in small cell lung carcinoma
-
批准号:9122074
-
项目类别:
-
资助金额:$37.1万
-
财政年份:2016
-
负责人:JULIEN SAGE
-
依托单位:
Molecular and cellular mechanisms of SCLC metastasis
-
批准号:9353182
-
项目类别:
-
资助金额:$44.19万
-
财政年份:2016
-
负责人:JULIEN SAGE
-
依托单位:
Molecular and cellular mechanisms of Merkel Cell Carcinoma development
-
批准号:8285754
-
项目类别:
-
资助金额:$17.44万
-
财政年份:2012
-
负责人:JULIEN SAGE
-
依托单位:
Molecular and cellular mechanisms of Merkel Cell Carcinoma development
-
批准号:8547037
-
项目类别:
-
资助金额:$19.62万
-
财政年份:2012
-
负责人:JULIEN SAGE
-
依托单位:
METHYLATION OF THE RETINOBLASTOMA TUMOR SUPPRESSOR BY SMYD2
-
批准号:8365918
-
项目类别:
-
资助金额:$1.28万
-
财政年份:2011
-
负责人:JULIEN SAGE
-
依托单位:
The RB Gene Family in Cancer Initiation
-
批准号:7909765
-
项目类别:
-
资助金额:$16.53万
-
财政年份:2009
-
负责人:JULIEN SAGE
-
依托单位:
The RB Gene Family in Cancer Initiation
-
批准号:7620096
-
项目类别:
-
资助金额:$27.8万
-
财政年份:2006
-
负责人:JULIEN SAGE
-
依托单位:
The RB Gene Family in Cancer Initiation
-
批准号:7145332
-
项目类别:
-
资助金额:$28.11万
-
财政年份:2006
-
负责人:JULIEN SAGE
-
依托单位:
The RB Gene Family in Cancer Initiation
-
批准号:7247078
-
项目类别:
-
资助金额:$27.45万
-
财政年份:2006
-
负责人:JULIEN SAGE
-
依托单位:
The RB pathway in liver cancer
-
批准号:8676681
-
项目类别:
-
资助金额:$26.96万
-
财政年份:2006
-
负责人:JULIEN SAGE
-
依托单位:
The RB pathway in liver cancer
-
批准号:8450741
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2006
-
负责人:JULIEN SAGE
-
依托单位:
海外基金